KaliVir Immunotherapeutics Receives FDA Approval for Investigational New Drug VET3-TGI in Solid Tumor Immunotherapy.

Approved on August 28, 2020, somapacitan (Sogroya) offers a convenient once-weekly injection, improving adherence and quality of life for patients.

Jul 5th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Approved on August 26, 2020, clascoterone (Winlevi) offers a novel mechanism of action by inhibiting androgen receptors in the skin, reducing oil production and inflammation associated with acne.

Idorsia’s JERAYGO (aprocitentan) approved in Europe as the first and only ERA for resistant hypertension treatment.

Approved on August 7, 2020, oliceridine (Olinvyk) is intended for patients who have not found relief with other treatments.

TauRx Pharmaceuticals Ltd has revealed the filing of a Marketing Authorisation Application in the UK for hydromethylthionine mesylate (HMTM).

risdiplam FDA approval on August 7, 2020, has provided new hope and convenience for individuals affected by SMA.

Formycon AG, together with their licensing partner Klinge Biopharma GmbH, has disclosed that the FYB203/AHZANTIVE (aflibercept-mrbb), a biosimilar to Eylea, has received approval from the U.S. Food and Drug Administration.

tafasitamab FDA approval on July 31, 2020, provides hope for patients with limited treatment options, though ongoing studies are necessary to fully understand its long-term efficacy and safety.

Ubix Therapeutics and Yuhan unveil an exclusive licensing deal for UBX-103, an oral AR degrader to treat metastatic castration-resistant prostate cancer.

Approved by the FDA on July 24, 2020, it utilizes innovative CAR-T cell technology to target and eliminate cancer cells, although it comes with significant risks and side effects that require careful management by healthcare professionals.